ASCO GI 2020: Abstract Recommendations From Dr. Jun Gong
Dr. Jun Gong of Cedars-Sinai Medical Center recommends the following abstracts being presented at the ASCO Gastrointestinal Cancers Symposium held in San Francisco Thursday, January 23, through Saturday, January 25, 2020.
Thursday, January 23, 2020; 1:30 PM–3:00 PM
Oral Abstract Session A: Esophageal and Gastric Cancer
278 Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). MH Moehler, M Dvorkin, M Ozguroglu, et al
281 A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. MCCM Hulshof, D Geijsen, T Rozema, et al
Friday, January 24, 2020; 7:00 AM–7:45 AM
Rapid Abstract Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
478 Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, V Zagonel, A Santoro, et al
604 First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs). N Pavlakis, DT Ransom, D Wyld, et al
Friday, January 24, 2020; 1:30 PM–3:00 PM
Oral Abstract Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
476 Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). PR Galle, RS Finn, S Qin, et al
638 HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). MA Tempero, E Van Cutsem, D Sigal, et al
Saturday, January 25, 2020; 7:00 AM–7:45 AM
Rapid Abstract Session C: Anal and Colorectal Cancer
10 Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR). F Pages, T Andre, J Taieb, et al
95 Randomized phase II trial of CAPOX with continuous versus intermittent use of oxaliplatin as an adjuvant chemotherapy after curative resection of stage II/III colon cancer (CCOG-1302 study). M Nakamura, G Nakayama, K Ishigure, et al
Saturday, January 25, 2020; 10:45 AM–12:15 PM
Oral Abstract Session C: Anal and Colorectal Cancer
1 Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study. A Marabelle, PA Cassier, M Fakih, et al
7 A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS). Y Kanemitsu, K Shitara, J Mizusawa, et al
12 Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification—A pooled analysis of TRIBE and TRIBE2 studies by GONO. G Zucchelli, R Moretto, D Rossini, et al
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: